Original Research ArticleEvaluation of mucoadhesive oral films containing Nystatin (cas 1400-61-9)
-
Add time:09/05/2019 Source:sciencedirect.com
The aim of the presented research was the preparation and in vitro and in vivo evaluation of mucoadhesive oral films containing nystatin. Multivariate data analysis was used to evaluate an innovative approach, in which a combination of different mucoadhesive polymers was employed. The purpose of this was to assess the effects of such a combination on non-woven insoluble carmellose textile as a drug-release modifier in the structure of the film.It was observed that the mucoadhesive films prepared using polyethylene oxide were more plastic, showed less mechanical resistance and shorter in vitro residence time in comparison with films containing sodium carmellose. The textile used in films containing sodium carmellose significantly prolonged both in vitro and in vivo residence times in rabbits from 50 ± 4 min until 74 ± 4 min and from 48 ± 6 until 80 ± 4 min, respectively. A higher degree of substitution by the acid carboxymethyl group of the textile resulted in slower nystatin dissolution, longer in vitro and in vivo residence times, and higher tensile strength. Textural parameters tensile strength and tensile deformation in conjunction with linear discriminant analysis were able to distinguish the degree of substitution of the textile due to its impact on the studied parameters.
We also recommend Trading Suppliers and Manufacturers of Nystatin (cas 1400-61-9). Pls Click Website Link as below: cas 1400-61-9 suppliers
Prev:Development of a gum base formulation for Nystatin (cas 1400-61-9); a new drug delivery approach for treatment of oral candidiasis
Next:A promising Nystatin (cas 1400-61-9) nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Preparation, physicochemical characterization and anti-fungal evaluation of the Nystatin (cas 1400-61-9)-loaded Eudragit RS100/PLGA nanoparticles09/09/2019
- The role of sterols in the lipid vesicle response induced by the pore-forming agent Nystatin (cas 1400-61-9)09/08/2019
- Identification of multi-targeted anti-migraine potential of Nystatin (cas 1400-61-9) and development of its brain targeted chitosan nanoformulation09/07/2019
- A promising Nystatin (cas 1400-61-9) nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis09/06/2019
- Development of a gum base formulation for Nystatin (cas 1400-61-9); a new drug delivery approach for treatment of oral candidiasis09/04/2019
- Stability and efficacy of combined Nystatin (cas 1400-61-9) and chlorhexidine against suspensions and biofilms of Candida albicans09/03/2019
- Case ReportA Drug–drug Interaction Between Cyclosporine and Nystatin (cas 1400-61-9)09/02/2019
- Comparison of the efficacy of indocyanine green-mediated photodynamic therapy and Nystatin (cas 1400-61-9) therapy in treatment of denture stomatitis09/01/2019